Age-Related Macular Degeneration

We break down 5 top trials to keep an eye on at ASRS 2024, taking place in Stockholm, Sweden from July 17 to 20, 2024.

A case series analysis indicated that switching from aflibercept to faricimab could be a safe and effective option for patients with treatment-resistant nAMD.

Administrative claims database analysis revealed a lower AMD incidence in patients treated with JAK inhibitor therapy versus non–JAK-based immunotherapy.

Prior authorizations for the anti-VEGF therapies aflibercept, ranibizumab, and bevacizumab were almost always approved but delayed care for most patients.

Marking the end of a voluntary recall, the FDA approved updates to Susvimo regarding the ocular implant and refill needle.

Announced by Genentech on July 04, 2024, the prefilled, 6.0 mg syringe is designed to improve ease of administration and offer ophthalmologists with a ready-to-use version of the bispecific antibody.

Our June 2024 month-in-review includes the latest pipeline news, the impact of vision issues on public health, and expert-led insight on the latest in ophthalmology.

Across the Phase 2 ReCLAIM-2 trial, elamipretide demonstrated photoreceptor protection and the potential for visual function improvement in eyes with dry AMD.

Aflibercept-mrbb showed comparable safety, efficacy, pharmacokinetics, and immunogenicity compared with the reference product.

Arshad Khanani, MD describes the mechanism of action of elamipretide, an investigational product candidate for geographic atrophy in dry age-related macular degeneration.

Arshad Khanani, MD breaks down the current treatment options for geographic atrophy and provides insight into the therapeutic pipeline.

This month-in-review features an exclusive interview with Srinivas R. Sadda, MD, and promising data from studies on geographic atrophy, diabetic macular ischemia, diabetic retinopathy, and AMD.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

Factors, including social deprivation and race, significantly affected visit adherence for patients with nAMD across a large healthcare system.

At ARVO 2024, Deepayan Kar, MD, PhD, describes the potential of measuring contrast sensitivity function using a novel gaze tracking-based VR headset in AMD.

Disease characteristics in wet AMD at baseline were not linked to aflibercept 8 mg dosing interval extensions in the phase 3 PULSAR trial at 96 weeks.

At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.

The phase 2 trial failed to show improvement of ≥2-DRSS levels with the vorolanib intravitreal insert in patients with non-proliferative diabetic retinopathy.

This month's review focuses on digital technology use in ophthalmology, the association between vision impairment and mental health, and public health impacts in eye care.

Mendelian randomization analysis demonstrated a direct connection between rheumatoid arthritis and an increased risk of age-related macular degeneration.

Most patients with AMD and glaucoma demonstrated standard postural control and a lower fall risk than patients with vestibular disorders.

Despite the availability of anti-VEGF therapies, there is still a notable disease burden in older adults with vision-threatening retinal diseases.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our March 2024 ophthalmology month in review features a recap of the latest news from the ophthalmic pipeline.

Peter A. Campochiaro, MD, discusses the safety and tolerability of RGX-314 gene therapy in treating wet AMD and how these results inform pivotal clinical trials.

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

Deepak Sambhara, MD, discusses how clinical practice has responded to the introduction of aflibercept 8 mg and the significance of extended treatment intervals for patients with retinal diseases.

David M. Brown, MD, discusses the full one-year data from the PULSAR and PHOTON trials and the implications of aflibercept 8 mg for patients with AMD and DME.

Metformin demonstrated a protective effect against new-onset geographic atrophy, which persisted and was more pronounced in individuals without diabetes.

A cohort analysis in the UK observed no significant association between sildenafil use and AMD prevention in men with erectile dysfunction.